Joseph Jimenez thrives on competition, and that’s a good thing, because he’s now working in an industry that has never faced such fierce competition as it does today.
“The industry is really in a state of flux,” said Jimenez, the CEO of Novartis, the Swiss pharmaceutical giant. “On the one hand, you have increasing demand around the world; we have the aging population and we have increased chronic illness in emerging markets. At the same time, you have financial systems around the world and payers that are trying to contain costs.”
Jimenez had been with Novartis for about three years as head of the company’s consumer health division – the group in charge of the company’s over-the-counter business with drugs like Excedrin and Theraflu –when he was asked to lead the company’s pharmaceutical division.Read More »from Novartis CEO is a quick study—and he had to be